ConductScience.org, home

Paper38414432

Friend or foe? Reciprocal regulation between E3 ubiquitin ligases and deubiquitinases.

Bolhuis DL and 2 others. Biochem Soc Trans, 2024. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Friend or foe? Reciprocal regulation between E3 ubiquitin ligases and deubiquitinases. Papers, record 38414432. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38414432

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Friend or foe? Reciprocal regulation between E3 ubiquitin ligases and deubiquitinases.
PubMed
Journal
Biochem Soc Trans
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.89, provisional
iCite
Revised in PubMed
2025-03-17
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bolhuis DLDerek Lhttps://orcid.org/0000-0002-9062-9739
2Emanuele MJMichael J
3Brown NGNicholas Ghttps://orcid.org/0000-0002-6141-0164

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ubiquitin-Protein LigasesMajor topic
Deubiquitinating EnzymesMajor topic
UbiquitinationMajor topic
Humans
Animals
Ubiquitin
Autophagy
Protein Processing, Post-Translational

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 GM120309NIGMS NIH HHSUnited StatesR01GM120309PubMed and NIHNIH RePORTER
R35 GM128855NIGMS NIH HHSUnited StatesR35GM128855PubMed and NIHNIH RePORTER
T32 GM008570NIGMS NIH HHSUnited StatesT32GM008570PubMed and NIHNIH RePORTER

Download CSV of grants

References445

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123758787TRAF molecules in cell signaling and in human diseases.J Mol Signal2013https://conductscience.org/library/papers/23758787PubMed
225547493USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition.Int J Mol Sci2014https://conductscience.org/library/papers/25547493PubMed
315334086The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.Nat Immunol2004https://conductscience.org/library/papers/15334086PubMed
431056254Ubiquitin-specific protease 3 targets TRAF6 for deubiquitination and suppresses IL-1β induced chondrocyte apoptosis.Biochem Biophys Res Commun2019https://conductscience.org/library/papers/31056254PubMed
526169834Deubiquitinase USP47/UBP64E Regulates β-Catenin Ubiquitination and Degradation and Plays a Positive Role in Wnt Signaling.Mol Cell Biol2015https://conductscience.org/library/papers/26169834PubMed
629326710Ubiquitin-Specific Protease 14 Negatively Regulates Toll-Like Receptor 4-Mediated Signaling and Autophagy Induction by Inhibiting Ubiquitination of TAK1-Binding Protein 2 and Beclin 1.Front Immunol2017https://conductscience.org/library/papers/29326710PubMed
731044085USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia.Cell Discov2019https://conductscience.org/library/papers/31044085PubMed
835022505Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced apoptosis by stabilizing BIRC3 in non-small cell lung cancer.Lab Invest2022https://conductscience.org/library/papers/35022505PubMed
924777531USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses.Nat Immunol2014https://conductscience.org/library/papers/24777531PubMed
1036976509The Interaction of OTUB1 and TRAF3 Mediates NLRP3 Inflammasome Activity to Regulate TGF-β1-induced BEAS-2B Cell Injury.Appl Biochem Biotechnol2023https://conductscience.org/library/papers/36976509PubMed
1121247385SCF E3 ubiquitin ligases as anticancer targets.Curr Cancer Drug Targets2011https://conductscience.org/library/papers/21247385PubMed
1217038327The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X.J Biol Chem2006https://conductscience.org/library/papers/17038327PubMed
1318977328Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation.Cancer Cell2008https://conductscience.org/library/papers/18977328PubMed
1425403879Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system.Cell Mol Life Sci2015https://conductscience.org/library/papers/25403879PubMed
1537202390FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37202390PubMed
1629018447TRIM25 in the Regulation of the Antiviral Innate Immunity.Front Immunol2017https://conductscience.org/library/papers/29018447PubMed
1732683298Ubiquitin specific protease 5 negatively regulates the IFNs-mediated antiviral activity via targeting SMURF1.Int Immunopharmacol2020https://conductscience.org/library/papers/32683298PubMed
1820940148The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.Hum Mol Genet2011https://conductscience.org/library/papers/20940148PubMed
1925716680Usp28 counteracts Fbw7 in intestinal homeostasis and cancer.Cancer Res2015https://conductscience.org/library/papers/25716680PubMed
2018952891HSV ICP0 recruits USP7 to modulate TLR-mediated innate response.Blood2009https://conductscience.org/library/papers/18952891PubMed

See all 445 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42881390It takes two to tango: the intersection of deubiquitinases and m6A modification in cancer.Mol Cancer2026https://conductscience.org/library/papers/42881390PubMed
42817983Substrate Profiling of RNF216 Uncovers a Translation-Linked OTUD4 Regulatory Axis.bioRxiv2026https://conductscience.org/library/papers/42817983PubMed
42494871Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42494871PubMed
42302908Proteome-wide Ubiquitinome Profiling Reveals Substrate-specific Dynamics Within the USP7 Network.Mol Cell Proteomics2026https://conductscience.org/library/papers/42302908PubMed
41637663Cardiomyocyte-Derived USP20 Attenuates Diabetic Cardiomyopathy by Facilitating the Degradation of STING and Mitigating STING-Mediated Inflammation.FASEB J2026https://conductscience.org/library/papers/41637663PubMed
40703447The ubiquitin code of RAS proteins: Decoding its role in cancer progression.iScience2025https://conductscience.org/library/papers/40703447PubMed
40379725USP37 prevents unscheduled replisome unloading through MCM complex deubiquitination.Nat Commun2025https://conductscience.org/library/papers/40379725PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38414432

GET https://conductscience.org/api/papers/v1/38414432/references?page=2